Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay
出版年份 2017 全文链接
标题
Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay
作者
关键词
Enzyme-linked immunoassays, DNA damage, Cancer treatment, Phosphorylation, Drug therapy, Histones, Nuclear staining, Ionizing radiation
出版物
PLoS One
Volume 12, Issue 2, Pages e0171582
出版商
Public Library of Science (PLoS)
发表日期
2017-02-04
DOI
10.1371/journal.pone.0171582
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187
- (2016) Eric X. Chen et al. INVESTIGATIONAL NEW DRUGS
- Pharmacodynamic analyses in a multi-laboratory network: lessons from the poly(ADP-ribose) assay
- (2016) Katherine V. Ferry-Galow et al. SEMINARS IN ONCOLOGY
- Recent developments in the use of γ -H2AX as a quantitative DNA double-strand break biomarker
- (2016) Christophe E. Redon et al. Aging-US
- A global reference for human genetic variation
- (2015) Richard A. Gibbs et al. NATURE
- The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis
- (2015) Stephanie Hehlgans et al. Radiation Oncology
- Proteomic profiling identifies specific histone species associated with leukemic and cancer cells
- (2015) Rajbir Singh et al. Clinical Proteomics
- Histone Variants Enriched in Oocytes Enhance Reprogramming to Induced Pluripotent Stem Cells
- (2014) Toshie Shinagawa et al. Cell Stem Cell
- The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks
- (2014) M. Tahara et al. MOLECULAR CANCER THERAPEUTICS
- High Resolution Copy Number Variation Data in the NCI-60 Cancer Cell Lines from Whole Genome Microarrays Accessible through CellMiner
- (2014) Sudhir Varma et al. PLoS One
- NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses
- (2014) William C. Reinhold et al. PLoS One
- Apoptosis and Molecular Targeting Therapy in Cancer
- (2014) Mohamed Hassan et al. Biomed Research International
- The Exomes of the NCI-60 Panel: A Genomic Resource for Cancer Biology and Systems Pharmacology
- (2013) O. D. Abaan et al. CANCER RESEARCH
- Histone variants in pluripotency and disease
- (2013) P. J. Skene et al. DEVELOPMENT
- γ-H2AX and other histone post-translational modifications in the clinic
- (2012) Christophe E. Redon et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set
- (2012) W. C. Reinhold et al. CANCER RESEARCH
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
- (2011) S. Kummar et al. CANCER RESEARCH
- Multispectral imaging flow cytometry reveals distinct frequencies of γ-H2AX foci induction in DNA double strand break repair defective human cell lines
- (2011) Emma C. Bourton et al. CYTOMETRY PART A
- Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
- (2011) Jens Samol et al. INVESTIGATIONAL NEW DRUGS
- Poly(ADP-ribose) polymerase and XPF–ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells
- (2011) Yong-Wei Zhang et al. NUCLEIC ACIDS RESEARCH
- Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells
- (2011) Jiuping Ji et al. PLoS One
- Histone H2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
- (2010) C. E. Redon et al. CLINICAL CANCER RESEARCH
- Development of a Validated Immunofluorescence Assay for H2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity
- (2010) R. J. Kinders et al. CLINICAL CANCER RESEARCH
- Whole cell-ELISA to measure the γH2AX response of six aneugens and eight DNA-damaging chemicals
- (2010) Kaori Matsuzaki et al. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
- RAD18 transmits DNA damage signalling to elicit homologous recombination repair
- (2009) Jun Huang et al. NATURE CELL BIOLOGY
- DNA Damage, Aging, and Cancer
- (2009) Jan H.J. Hoeijmakers NEW ENGLAND JOURNAL OF MEDICINE
- Histone macroH2A isoforms predict the risk of lung cancer recurrence
- (2009) J C Sporn et al. ONCOGENE
- Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts
- (2008) R. J. Kinders et al. CLINICAL CANCER RESEARCH
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
- (2008) Keith A. Menear et al. JOURNAL OF MEDICINAL CHEMISTRY
- Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment
- (2008) Clorinda Schettino et al. Expert Review of Respiratory Medicine
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation